Page last updated: 2024-10-25

cimetidine and Tauopathies

cimetidine has been researched along with Tauopathies in 1 studies

Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.

Tauopathies: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Di Pietro, O1
Pérez-Areales, FJ1
Juárez-Jiménez, J1
Espargaró, A1
Clos, MV1
Pérez, B1
Lavilla, R1
Sabaté, R1
Luque, FJ1
Muñoz-Torrero, D1

Other Studies

1 other study available for cimetidine and Tauopathies

ArticleYear
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
    European journal of medicinal chemistry, 2014, Sep-12, Volume: 84

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response

2014